Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human amniotic epithelial cell therapy - Shanghai iCELL Biotechnology

Next Previous
Drug Profile

Human amniotic epithelial cell therapy - Shanghai iCELL Biotechnology

Alternative Names: hAECs; hAESCs; Human amniotic epithelial stem cell therapy - Shanghai iCELL Biotechnology

Latest Information Update: 11 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai iCELL Biotechnology
  • Developer Peking University People's Hospital; Shanghai iCELL Biotechnology
  • Class Cell therapies; Stem cell therapies; Urologics
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Parkinson's disease
  • No development reported Genitourinary disorders; Graft-versus-host disease

Most Recent Events

  • 05 Jun 2024 Nanfang Hospital, Southern Medical University and Shanghai iCELL Biotechnology plans a phase 0 trial for Graft-versus-host disease (Prevention, In adult, In the elderly) in July 2024 (IV-Infusion) (NCT06444022)
  • 28 Jul 2023 No recent reports of development identified for phase-I development in Graft-versus-host-disease(In adolescents, In children, In the elderly, Prevention, In adults) in China (IV, Infusion)
  • 16 Feb 2023 Phase-I clinical trials in Parkinson's disease (In adults, In the elderly) in China (Intraventricular)(NCT05691114)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top